Argos Therapeutics Inc. (ARGS) Major Shareholder International S. Pharmstandard Acquires 43,618 Shares
Argos Therapeutics Inc. (NASDAQ:ARGS) major shareholder International S. Pharmstandard acquired 43,618 shares of Argos Therapeutics stock in a transaction dated Thursday, September 29th. The shares were purchased at an average cost of $4.56 per share, with a total value of $198,898.08. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Large shareholders that own more than 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Shares of Argos Therapeutics Inc. (NASDAQ:ARGS) opened at 4.97 on Friday. The stock has a 50 day moving average price of $4.78 and a 200-day moving average price of $5.93. The firm’s market capitalization is $204.74 million. Argos Therapeutics Inc. has a 52-week low of $1.61 and a 52-week high of $13.97.
Argos Therapeutics (NASDAQ:ARGS) last issued its quarterly earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by $0.05. Equities analysts forecast that Argos Therapeutics Inc. will post ($1.56) EPS for the current year.
Several research firms have recently weighed in on ARGS. Needham & Company LLC reaffirmed a “buy” rating and set a $11.00 price objective on shares of Argos Therapeutics in a research report on Friday, June 17th. Zacks Investment Research raised Argos Therapeutics from a “hold” rating to a “buy” rating and set a $5.00 price objective for the company in a research report on Monday, August 15th. FBR & Co reduced their price objective on Argos Therapeutics from $14.00 to $13.00 and set an “outperform” rating for the company in a research report on Thursday, August 11th. Finally, Piper Jaffray Cos. reissued an “overweight” rating and set a $11.00 price target on shares of Argos Therapeutics in a research report on Monday, June 20th. Eight analysts have rated the stock with a buy rating, Argos Therapeutics has an average rating of “Buy” and a consensus price target of $11.50.
Hedge funds and other institutional investors have recently modified their holdings of the company. Schwab Charles Investment Management Inc. acquired a new position in shares of Argos Therapeutics during the second quarter valued at $137,000. Bridgeway Capital Management Inc. boosted its position in shares of Argos Therapeutics by 66.9% in the second quarter. Bridgeway Capital Management Inc. now owns 135,924 shares of the biopharmaceutical company’s stock valued at $833,000 after buying an additional 54,500 shares in the last quarter. KCG Holdings Inc. acquired a new position in shares of Argos Therapeutics during the second quarter valued at $163,000. State Street Corp acquired a new position in shares of Argos Therapeutics during the second quarter valued at $741,000. Finally, BlackRock Institutional Trust Company N.A. acquired a new position in shares of Argos Therapeutics during the second quarter valued at $363,000. Institutional investors and hedge funds own 11.05% of the company’s stock.
Argos Therapeutics Company Profile
Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.
Receive News & Stock Ratings for Argos Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics Inc. and related stocks with our FREE daily email newsletter.